MADRIGAL PHARMACEUTICALS, INC. Q2 2026: Revenue $364.25M, EPS ($1.99) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Madrigal Pharmaceuticals reported Q2 2026 results with product revenue rising 71.2% year-over-year to $364.25M, driven by strong U.S. demand for Rezdiffra. The company posted a net loss of $57.94M and diluted EPS of ($1.99). Key developments include the European launch of Rezdiffra, expansion of the U.S. sales force, and pipeline advancements such as initiating Phase 1 studies for MGL-2086.
MADRIGAL PHARMACEUTICALS, INC. reported second-quarter 2026 results with product revenue rising to $364.25M, up 71.2% year over year, while the company posted a net loss of ($57.94M) and diluted EPS of ($1.99) for the quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $364.25M | $212.8M | 71.2% |
| Net income² | ($57.94M) | ($42.28M) | (37%) |
| Diluted EPS³ | ($1.99) | ($1.5) | (32.7%) |
¹ Reported as “Product revenue, net”. ² Reported as “Net loss”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue Growth: Product revenue rose to $364.3M in Q2 2026, driven by strong U.S. demand for Rezdiffra.
- Commercial Expansion: Launched Rezdiffra in Germany in September 2025 and expanded the U.S. field force to include endocrinologists.
- Clinical & Brand Momentum: Real-world data and Phase 3 analyses showed improvements in liver stiffness and lipid profiles, supporting the clinical benefit narrative.
- Pipeline & Business Development: Acquired or licensed multiple assets including MGL-0795, MGL-2086, ervogastat and six siRNA programs; initiated a Phase 1 study for MGL-2086 and nominated an siRNA candidate.
- Manufacturing & Operations: Increased manufacturing activity contributed to higher cost of sales and included a $10.4M work-in-process write-down; European drug product manufacturing is engaged.
Original SEC Filing: MADRIGAL PHARMACEUTICALS, INC. [ MDGL ] - 10-Q - Jul. 30, 2026